Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
348 participants
INTERVENTIONAL
2022-06-27
2026-07-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Hypertension is a contributing factor, and nonadherence to medication could amplify it.
There are several ways to assess adherence to treatment: the use of declarative questionnaires, a method not without criticism because it is subject to the subjectivity of the declaration by the patient; and drug dosages, a standard technique, although insufficiently disseminated due to the high cost and greater weight of the survey protocols. Drug non-compliance is multifactorial. In addition, it has been shown that having undesirable drug effects and / or being afraid of developing them is one of the major causes of non-compliance with antihypertensive treatments.
The investigators hypothesize that DS is significantly more common among hypertensive women treated with non-observers compared to hypertensive women treated with observers.
The main objective is to compare the prevalence of sexual dysfunction between a group of hypertensive women treated as observers and a group of hypertensive women treated as non-observers.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Descriptive Study of Drug Compliance in Uncontrolled Hypertensive Patients
NCT03348878
Feasibility of a Program on a Nurse-led Telephone 6-month-follow-up for Uncontrolled Hypertensive Women
NCT03963934
Adherence to Antihypertensive Therapy--Data Analyses
NCT00006552
Treatment Adherence and Blood Pressure Outcome Among Hypertensive Out-patients
NCT03476512
Medication Adherence in Hypertension Study
NCT00688350
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Hypertensive women
Blood sample for the determination of antihypertensives or their metabolites.
15 ml of Blood sample for the determination of antihypertensives or their metabolites
Questionnaire on sexual activity
Questionnaire on sexual activity in women
Scale on hospital anxiety and depression
Scale on hospital anxiety and depression to detect anxious and depressive symptoms (14 questions)
Morisky Questionaire
anti-hypertensive medication compliance questionnaire
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Blood sample for the determination of antihypertensives or their metabolites.
15 ml of Blood sample for the determination of antihypertensives or their metabolites
Questionnaire on sexual activity
Questionnaire on sexual activity in women
Scale on hospital anxiety and depression
Scale on hospital anxiety and depression to detect anxious and depressive symptoms (14 questions)
Morisky Questionaire
anti-hypertensive medication compliance questionnaire
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Hospitalized or received in consultation for the management of hypertension treated in one of the hypertension and therapeutic, nephrology or cardiology departments participating in the study, with confirmed hypertension, treated with the following dosable antihypertensive agent(s): diltiazem, verapamil, acebutolol, atenolol, nébivolol, bisoprolol, metoprolol, propranolol, amiloride, furosemide, hydrochlorothiazide, indapamide, spironolactone, spironolactone, Lorsartan, Irbesartan, Ramipril, Perindopril, Amlodipine,
* Having signed the informed consent form.
* Beneficiary or affiliated to a French Social insurance
Exclusion Criteria
* Patients under guardianship/trusteeship/protection of justice,
* Patients with diagnosed and treated psychosis or depression, - Pregnant or nursing women.
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Toulouse
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Delphine LAZARO-VERGE, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital, Toulouse
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
LAZARO Delphine
Toulouse, CHU de Toulouse, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RC31/19/0553
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.